Navigation Links
VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
Date:7/30/2009

BEDFORD, Mass., July 30 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that scientists reporting in the July 31 issue of SCIENCE have discovered a key disease-related biologic pathway using an integrated and innovative array of in vitro readouts and advanced in vivo imaging technologies. The newly reported biologic pathway relates to monocyte deployment from the spleen to inflammatory sites, including myocardial infarction. The findings are expected to open up new areas of research and potentially advance therapeutic approaches to key disease areas including inflammation and myocardial injury.

In the SCIENCE report, entitled "Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites," researchers at the Massachusetts General Hospital's Center for Systems Biology found that monocytes were held in concentration in the spleen and released to injured tissue sites in the body to participate in wound healing. As presented in the findings, the reporting scientists discovered and detailed the biologic pathway through the use of a series of advanced and integrated in vitro assays, microscopic readouts, and in vivo imaging methodologies, including Magnetic Resonance (MR) imaging combined with quantitative Fluorescence Molecular Tomographic (FMT) imaging. Used together in a series of novel scientific models, the researchers developed correlated data sets to both identify this previously unidentified splenic reservoir of monocytes, and demonstrate the monocyte deployment to inflammatory sites in vivo. In the in vivo data analysis, non-invasive, quantitative FMT imaging using novel fluorescent molecular imaging agents, combined with MR imaging, clearly demonstrated not only the location, but also the biological activity of the recruited splenic monocytes at the disease site, thus helping to confirm "unambiguously the fate of monocytes from the spleen to the heart."

"We see the integration of in vitro and in vivo readouts becoming increasingly important in research today, and we are extremely pleased that our FMT quantitative in vivo imaging technology and activatable in vivo imaging agents were able to help the research team answer some of the key questions about this important biologic pathway in vivo," said Dr. Jeffrey Peterson, VP, Applied Biology at VisEn Medical. "When cardiac molecular imaging data from the FMT was combined with MRI imaging, the researchers were able to create a fused molecular and anatomical imaging map of the heart to identify and quantify biomarkers of monocyte activity in vivo. These results enabled an important data correlation that further enhanced the integrated array of in vitro assays and microscopy-based readouts of this important pathway."

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at www.visenmedical.com.


'/>"/>
SOURCE VisEn Medical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
2. Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
3. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
4. Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
5. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
6. Midwest Research Institute Launches Clinical Molecular Diagnostics Laboratory
7. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
8. Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State
9. Verification Studies of IntelligentMDxs Proprietary Molecular Diagnostic Assay Process Have Been Completed
10. Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source
11. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... BioLife Solutions , Inc. (NASDAQ: BLFS ), the ... and tissue hypothermic storage and cryopreservation freeze ... and CEO, will be presenting at two investment conferences in ... th Annual Global Investment Conference on Tuesday, September 12th, ... conference is being held at the New York Palace Hotel ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... September 26, 2017 , ... Data Integrity: , The Key to FDA ... 2017 – Arlington, VA, http://www.fdanews.com/fdadataintegrity , Consider this situation. ... electronic records may not be trustworthy and reliable … a more detailed evaluation may ...
(Date:9/26/2017)... Milford, PA (PRWEB) , ... September 26, 2017 , ... ... month in Chicago, called “The Magic of Fat,” revealed not only the latest about ... might prove to be an evolution in cosmetic medicine. , “Fat really is magical, ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Good Morning Sunshine!: Finding ... and overcoming obstacles. “Good Morning Sunshine!: Finding Strength and Comfort in God” is the ... psychology from Fort Hays Sate University, who has worked at a local mental health ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Sonflower Submission”: a ... nature to the inevitable destinations of negativity, complaining and the need to always be ... take effect in order for a lesson in stress-less living to be learned. ...
(Date:9/26/2017)... ... ... out for Daddy is a moving story of a family's unconditional love for each ... for Daddy” is the creation of published author Debra Titus, who has lived in ... her to write this book. , Published by Christian Faith Publishing, Debra Titus’s new ...
Breaking Medicine News(10 mins):